Heart drug trial aims to ease debilitating condition
NCT ID NCT07240844
Summary
This study is testing whether a drug called Enavogliflozin can help control amyloid cardiomyopathy, a serious disease where abnormal proteins build up in the heart. About 68 adults with this condition and heart failure symptoms will take the drug or a placebo for 12 weeks each, with a break in between. Researchers will measure changes in symptoms, walking ability, and heart health markers to see if the drug is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
Seoul, 06351, South Korea
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, 06591, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.